Financial Performance - In the first half of 2025, the company's operating revenue was 11.00 billion CNY, a year-on-year decrease of 9.97% [2] - Net profit attributable to shareholders was 1.34 billion CNY, an increase of 7.56% year-on-year [2] - The net profit after deducting non-recurring gains and losses increased by 13.28% [2] - Operating cash flow was 1.55 billion CNY, with a weighted average return on equity of 6.78% [2] Sales Growth Drivers - Sales of the main product, An Nao Wan/Pian, increased by over 30% year-on-year [3] - Revenue from potassium chloride sustained-release tablets also grew by over 30% [3] - The sales of the drug Siglitin Metformin sustained-release tablets have expanded to over 600 terminals, with expected continued growth [3] Cost Management - Sales expenses decreased by 31.28% to 294 million CNY [3] - Management expenses fell by 21.58% to 56.75 million CNY [3] - Financial expenses reduced from 60.13 million CNY to 48.03 million CNY [3] Future Strategies - Focus on existing product growth, particularly for Luguapeptide injection and multi-vitamin injections [3] - Accelerate the sales channel expansion for Siglitin Metformin sustained-release tablets and explore new markets for Meloxicam tablets [3] - New product Pema Bet tablets expected to launch in September, with high market expectations [3] - The company aims to maintain low levels of financial, management, and sales expenses [3] Market Expectations - Pema Bet tablets projected to enter the national catalog in Q4 2025, with significant market potential [4] - Siglitin Metformin sustained-release tablets expected to achieve sales of approximately 100 million CNY by year-end [4] - An Nao Wan/Pian expected to exceed 10 million boxes in sales, with a target of over 1 billion CNY in the next five years [6] International Expansion - The company has accumulated experience in international cooperation over the past decade and plans to continue exploring new opportunities [7] - Sodium creatine phosphate sales in Central Asia generated 2.46 million CNY in revenue in the first half of 2025 [7] Cost Efficiency - Sales expense ratio has decreased to 26.76% due to refined management and drug procurement policies [8] - Management expense ratio is among the lowest in the industry, with potential for further reduction [8] E-commerce Development - The company has established a professional e-commerce team, expecting online sales to contribute approximately 20% of product revenue [8]

Group 1 - The gene sequencing sector experienced a decline of 3.38%, ranking among the top losers in the concept sector as of the market close on August 27 [2][3] - Within the gene sequencing sector, major companies such as Guangshentang, Ruian Gene, and Puni Testing saw significant declines, while a few companies like Dean Diagnostics, Aiko Optoelectronics, and Kingmed Diagnostics recorded gains of 5.81%, 3.67%, and 2.11% respectively [2][3] - The gene sequencing sector faced a net outflow of 1.543 billion yuan from main funds, with 53 stocks experiencing net outflows, and five stocks seeing outflows exceeding 100 million yuan [3][4] Group 2 - Guangshentang led the outflow with a net withdrawal of 379 million yuan, followed by Anke Bio, Huace Testing, and Yuheng Pharmaceutical with net outflows of 189 million yuan, 118 million yuan, and 116 million yuan respectively [3][4] - On the other hand, the stocks with the highest net inflows included BGI Genomics, Kingmed Diagnostics, and Jiuzhoutong, attracting net inflows of 107 million yuan, 106 million yuan, and 79 million yuan respectively [3][5] - The overall market sentiment in the gene sequencing sector appears to be bearish, as indicated by the significant net outflows and the performance of major stocks within the sector [2][3]

Group 1 - The core viewpoint of the article highlights the growth in the number of enterprises in the chemical raw materials and chemical products manufacturing industry, which increased by 1,021 to a total of 26,860 enterprises in the first half of 2025, representing a year-on-year growth of 3.95% [1] - The proportion of chemical raw materials and chemical products manufacturing enterprises in the total industrial enterprises is 5.16% [1] - The report referenced is the "2025-2031 China Basic Chemical Raw Materials Industry Market Supply and Demand Situation and Investment Prospects Analysis Report" published by Zhiyan Consulting [1] Group 2 - The data indicates that the threshold for scale industrial enterprises has been raised from an annual main business income of 5 million yuan to 20 million yuan since 2011 [1] - Zhiyan Consulting is recognized as a leading industry consulting agency in China, providing comprehensive industry research reports, business plans, feasibility studies, and customized services [1] - The consulting firm emphasizes its commitment to delivering quality services and market insights to empower investment decisions [1]

Core Insights - Yuheng Pharmaceutical (002437.SZ) reported a total operating revenue of 1.1 billion yuan for the first half of 2025, ranking 37th among disclosed peers [1] - The company's net profit attributable to shareholders reached 134 million yuan, marking a year-on-year increase of 9.45 million yuan, or 7.56%, achieving three consecutive years of growth [1] - The net cash inflow from operating activities was 155 million yuan, ranking 33rd among disclosed peers [1] Financial Metrics - The latest debt-to-asset ratio is 28.70%, ranking 46th among disclosed peers, down 3.27 percentage points from the previous quarter and 2.96 percentage points from the same period last year [3] - The latest gross profit margin stands at 47.29% [3] - The return on equity (ROE) is 6.56%, ranking 23rd among disclosed peers, with a slight increase of 0.06 percentage points year-on-year [3] - The diluted earnings per share (EPS) is 0.06 yuan, an increase of 0.01 yuan from the same period last year, reflecting a 10.25% year-on-year growth [3] - The total asset turnover ratio is 0.38 times, ranking 9th among disclosed peers [3] - The inventory turnover ratio is 3.23 times, ranking 5th among disclosed peers, with an increase of 0.24 times year-on-year, achieving five consecutive years of growth [3] Shareholder Structure - The number of shareholders is 104,400, with the top ten shareholders holding a total of 490 million shares, accounting for 21.80% of the total share capital [3] - The top shareholders include: 1. Shen Zhenyu - 49.2 million shares 2. Guotai Junan Securities Co., Ltd. - 48.4 million shares 3. Yu Heng International Investments Corporation - 25.3 million shares 4. Oriental Keystone Investment Limited - 19.1 million shares 5. Hong Kong Central Clearing Limited - 13.9 million shares 6. Shanghai Fangyuan Dachuang Investment Partnership (Limited Partnership) - 13.7 million shares 7. Shanghai Fangyuan Dachuang Investment Partnership (Limited Partnership) - 13.5 million shares 8. Shanghai Fangyuan Dachuang Investment Partnership (Limited Partnership) - 12.7 million shares 9. Shanghai Fangyuan Dachuang Investment Partnership (Limited Partnership) - 12.5 million shares 10. Guoqi Ling - 9.8 million shares [3]

外资态度来看，本期较上一季度新披露的外资机构有 1 家 ，即香港中央结算有限公司。 2025年8月27日，誉衡药业(002437.SZ)发布2025年半年度报告。截至2025年8月26日，共有9个机构投资 者披露持有誉衡药业A股股份，合计持股量达3.75亿股，占誉衡药业总股本的16.69%。其中，机构投资 者包括国泰海通证券股份有限公司、YU HENG INTERNATIONAL INVESTMENTS CORPORATION、 ORIENTAL KEYSTONE INVESTMENT LIMITED、香港中央结算有限公司、上海方圆达创投资合伙企 业(有限合伙)-方圆-东方12号私募投资基金、上海方圆达创投资合伙企业(有限合伙)-方圆-东方27号私募 投资基金、上海方圆达创投资合伙企业(有限合伙)-方圆-东方6号私募投资基金、上海方圆达创投资合伙 企业(有限合伙)-方圆-东方22号私募投资基金、东源(天津)股权投资基金管理股份有限公司-东源投资财 富51号私募证券投资基金，机构投资者合计持股比例达16.69%。相较于上一季度，机构持股比例合计 上涨了0.35个百分点。 公募基金方面，本期较上一季未再披露的公募 ...

证券代码：002437 证券简称：誉衡药业 公告编号：2025-063 哈尔滨誉衡药业股份有限公司 2025 年半年度财务报告 2025 年 8 月 半年度报告是否经过审计 □是 否 公司半年度财务报告未经审计。 二、财务报表 财务附注中报表的单位为：元 1、合并资产负债表 编制单位：哈尔滨誉衡药业股份有限公司 2025 年 06 月 30 日 单位：元 第 1页 财务报告 一、审计报告 | 项目 | 期末余额 | 期初余额 | | --- | --- | --- | | 流动资产： | | | | 货币资金 | 302,061,136.78 | 481,962,600.35 | | 结算备付金 | | | | 拆出资金 | | | | 交易性金融资产 | 351,096,896.57 | 30,001,832.88 | | 衍生金融资产 | | | | 应收票据 | | 1,245,321.46 | | 应收账款 | 114,084,010.51 | 124,883,516.67 | | 应收款项融资 | 5,799,541.06 | 2,496,094.20 | | 预付款项 | 8,977,720.91 ...

哈尔滨誉衡药业股份有限公司 证券代码：002437 证券简称：誉衡药业 公告编号：2025-064 哈尔滨誉衡药业股份有限公司 2025 年半年度非经营性资金占用及其他关联资金往来情况汇总表 编制单位：哈尔滨誉衡药业股份有限公司 单位：万元 | 控股股东、实 | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 际控制人及其 | | | | | | | | | | | | 附属企业 | | | | | | | | | | | | 上市公司的子 | | | | | | | | | | | | 公司及其附属 | | | | | | | | | | | | 企业 | | | | | | | | | | | | 其他关联方及 | | | | | | | | | | | | 其附属企业 | | | | | | | | | | | | 总计 | - | - | - | - | - | - | - | | - - | - | | 法定代表人：国磊峰 | | | | 主管会计工作负责人：国磊峰 | ...

哈尔滨誉衡药业股份有限公司 证券代码：002437 证券简称：誉衡药业 公告编号：2025-066 哈尔滨誉衡药业股份有限公司 关于修订及新增制定公司部分制度的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 哈尔滨誉衡药业股份有限公司（以下简称"公司"）于 2025 年 8 月 25 日 召开的第七届董事会第四次会议审议通过了《关于修订及新增制定公司部分制度 的议案》，具体情况如下： 一、修订及新增制定部分制度情况 为全面贯彻落实最新法律法规要求，确保公司治理制度与监管规定保持同步， 根据《公司法》、《上市公司章程指引》、《深圳证券交易所股票上市规则》、 《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》 等相关法律法规与规范性文件的规定，结合公司实际情况，对部分公司制度进行 了修订，并新增制定了部分制度，本次修订完成后，原相关制度将同时废止。 | 序号 | 制度名称 | 类型 | 是否须提交股 | | --- | --- | --- | --- | | | | | 东大会审议 | | 1 | 股东会议事规则 | 修订 | 是 | ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：002437 证券简称：誉衡药业 公告编号：2025-068 哈尔滨誉衡药业股份有限公司 关于召开 2025 年第三次临时股东大会的通知 哈尔滨誉衡药业股份有限公司 2025 年 8 月 25 日，哈尔滨誉衡药业股份有限公司（以下简称"公司"）第 七届董事会第四次会议审议通过了《关于召开 2025 年第三次临时股东大会的议 案》。现就相关事宜公告如下： 一、召开会议基本情况 ㈠ 股东大会会议届次：2025 年第三次临时股东大会。 ㈢ 会议召开的合法、合规性：本次股东大会的召开已经公司第七届董事会 第四次会议审议通过，符合《公司法》、《公司章程》等相关规定。 ㈣ 召开时间： 1、现场会议时间：2025 年 9 月 11 日 15:00； 2、网络投票时间：2025 年 9 月 11 日； ⑴ 通过深圳证券交易所交易系统进行网络投票的时间为 2025 年 9 月 11 日 9:15—9:25，9:30—11:30 和 13:00—15:00； ⑵ 通过深圳证券交易所互联网系统投票的具体时间为：2025 年 ...

哈尔滨誉衡药业股份有限公司 证券代码：002437 证券简称：誉衡药业 公告编号：2025-060 哈尔滨誉衡药业股份有限公司 第六届监事会第十九次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2025 年 8 月 15 日，哈尔滨誉衡药业股份有限公司（以下简称"公司"）以 短信及电子邮件的方式向全体监事发出了《关于召开公司第六届监事会第十九次 会议的通知》及相关议案。 2025 年 8 月 25 日，第六届监事会第十九次会议以通讯方式召开。本次会议 应参加监事 3 人，实际参加监事 3 人。会议的召集、召开及表决程序符合《公司 法》、《公司章程》及《监事会议事规则》等有关规定。会议由监事会主席张超 主持，经与会监事认真审议及表决形成如下决议： 一、审议并通过了《关于 2025 年半年度报告全文及摘要的议案》，并发表 如下意见： 监事会对拟回购注销的激励对象名单及限制性股份数量进行了审核，公司本 次回购注销部分限制性股票符合公司《2024 年限制性股票激励计划》及相关法 律法规的规定，审议程序合法、合规，不会对公司的财务状况和经营成果产生实 第 ...